MAP3K4

Mitogen-activated protein kinase kinase kinase 4 · Q9Y6R4 · MAP3K4 on Sugi Atlas →

2,976 patent compounds predicted against MAP3K4, 2,796 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Aee-788 (SCHEMBL613755)	1.00	1/20
Aee-788 (SCHEMBL613756)	1.00	1/20
Adavosertib (SCHEMBL1504444)	1.00	1/20
Aee-788 (SCHEMBL1738023)	1.00	1/20
Gsk-1070916 (SCHEMBL4305006)	1.00	1/20
Encorafenib (SCHEMBL8228295)	1.00	1/20
Encorafenib (SCHEMBL8231398)	1.00	1/20
Encorafenib (SCHEMBL8512458)	1.00	1/20
Adavosertib (SCHEMBL1504996)	0.98	1/20
Adavosertib (SCHEMBL1504998)	0.98	1/20
SCHEMBL1815951	0.94	1/20
Adavosertib (SCHEMBL3579242)	0.94	1/20
SCHEMBL1811019	0.89	1/20
SCHEMBL1813967	0.89	1/20
SCHEMBL1813347	0.88	1/20
SCHEMBL1816446	0.88	1/20
SCHEMBL4316846	0.87	1/20
SCHEMBL8236122	0.87	1/20
SCHEMBL8236124	0.87	1/20
SCHEMBL1813878	0.86	1/20

Clinical trials — most relevant to MAP3K4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma	PHASE4	UNKNOWN
Molecular Mechanisms of Type 2 Diabetes Mellitus	PHASE4	COMPLETED
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Clinical Evaluation of the Effect of Metformin in Sepsis	PHASE3	UNKNOWN
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	PHASE1/PHASE2	SUSPENDED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations	PHASE2	ACTIVE_NOT_RECRUITING
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer	PHASE2	COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma	PHASE1/PHASE2	COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations	PHASE2	RECRUITING
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.	PHASE2	UNKNOWN
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer	PHASE2	UNKNOWN
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma	PHASE2	UNKNOWN
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	PHASE2	COMPLETED
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery	PHASE2	COMPLETED
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer	PHASE2	COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo	nan	UNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients	nan	COMPLETED
Molecular Analysis of Thoracic Malignancies	nan	ENROLLING_BY_INVITATION
Histiocytic Disorder Follow-up Study	nan	RECRUITING
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial	nan	RECRUITING
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
RASopathy Biorepository	nan	RECRUITING
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a MAP3K4 binder may also engage these)

Protein	Name	Similarity
O08648	—	1.000	O08648 →
Q6P9N1	—	1.000	Q6P9N1 →
Q9QXP4	—	0.999	Q9QXP4 →
F5H4B4	—	0.998	F5H4B4 →
A2AKX3	—	0.998	A2AKX3 →
Q9BXB7	—	0.997	Q9BXB7 →
Q60988	—	0.997	Q60988 →
Q96GY3	—	0.997	Q96GY3 →
A2ARZ3	—	0.997	A2ARZ3 →
Q5MNV8	—	0.997	Q5MNV8 →
O14299	—	0.997	O14299 →
Q9BW66	—	0.997	Q9BW66 →
Q8IWA6	—	0.997	Q8IWA6 →
A9CB91	—	0.997	A9CB91 →
Q9BYI3	—	0.997	Q9BYI3 →
Q0VDD8	—	0.997	Q0VDD8 →
Q80TA9	—	0.997	Q80TA9 →
B9EJV3	—	0.997	B9EJV3 →
Q9BVR0	—	0.997	Q9BVR0 →
P11824	—	0.996	P11824 →
E9Q555	—	0.996	E9Q555 →
Q5SQS8	—	0.996	Q5SQS8 →
Q5RA87	—	0.996	Q5RA87 →
Q9TTK4	—	0.996	Q9TTK4 →
A0JMD2	—	0.996	A0JMD2 →
Q9HCE0	—	0.996	Q9HCE0 →
Q9D979	—	0.996	Q9D979 →
Q5GJ75	—	0.996	Q5GJ75 →
Q9D9W0	—	0.996	Q9D9W0 →
Q28HY7	—	0.995	Q28HY7 →